ALSEN Stock Overview
A biotechnology company, develops drug candidates for the treatment of inner ear disorders in France. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
Sensorion SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.30 |
| 52 Week High | €0.97 |
| 52 Week Low | €0.29 |
| Beta | 1.3 |
| 1 Month Change | -46.44% |
| 3 Month Change | -57.00% |
| 1 Year Change | -59.32% |
| 3 Year Change | -50.49% |
| 5 Year Change | -63.38% |
| Change since IPO | -93.37% |
Recent News & Updates
Shareholder Returns
| ALSEN | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -13.0% | 7.8% | 5.4% |
| 1Y | -59.3% | -36.4% | -9.6% |
Return vs Industry: ALSEN underperformed the French Biotechs industry which returned -39.8% over the past year.
Return vs Market: ALSEN underperformed the French Market which returned -11.6% over the past year.
Price Volatility
| ALSEN volatility | |
|---|---|
| ALSEN Average Weekly Movement | 10.1% |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in FR Market | 11.2% |
| 10% least volatile stocks in FR Market | 2.7% |
Stable Share Price: ALSEN's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: ALSEN's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 63 | Nawal Ouzren | www.sensorion.com |
Sensorion SA, a biotechnology company, develops drug candidates for the treatment of inner ear disorders in France. The company’s product portfolio includes SENS-401 SSNHL, which has completed Phase 2b clinical trial for the treatment of Sudden Sensorineural Hearing Loss; SENS-401 CIO that is in Phase 2a clinical trial for the treatment of Cisplatin-Induced Ototoxicity; and SENS-401 Cochlear, which is in Phase 2a clinical which is an orally available small molecule protecting and preserving inner ear tissue from damage, responsible for hearing impairment. It is also developing OTOF-GT (SENS-501), a gene therapy development program that has completed Phase 1/2 clinical trial to restore hearing in people living with Otoferlin deficiency; and GJB2-GT, a gene therapy development program, which is in pre-clinical trial to restore hearing in people living with hearing loss due to mutations in the GJB2 gene.
Sensorion SA Fundamentals Summary
| ALSEN fundamental statistics | |
|---|---|
| Market cap | €90.45m |
| Earnings (TTM) | -€25.97m |
| Revenue (TTM) | €6.65m |
13.6x
P/S Ratio-3.5x
P/E RatioIs ALSEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALSEN income statement (TTM) | |
|---|---|
| Revenue | €6.65m |
| Cost of Revenue | €0 |
| Gross Profit | €6.65m |
| Other Expenses | €32.63m |
| Earnings | -€25.97m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.086 |
| Gross Margin | 100.00% |
| Net Profit Margin | -390.38% |
| Debt/Equity Ratio | 1.7% |
How did ALSEN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/14 05:33 |
| End of Day Share Price | 2025/04/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sensorion SA is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joseph Pantginis | H.C. Wainwright & Co. |
| Lucy-Emma Mary Codrington-Bartlett | Jefferies LLC |
| Thomas Guillot | Kepler Cheuvreux |